Experience with caspofungin in the treatment of persistent fungemia in neonates

被引：64

作者：

Natarajan G. ^{[1
]}

Lulic-Botica M. ^{[1
]}

Rongkavilit C. ^{[1
]}

Pappas A. ^{[1
]}

Bedard M. ^{[1
]}

机构：

[1] Department of Pediatrics, Children's Hospital of Michigan, Detroit, MI 48201

来源：

Journal of Perinatology | 2005年 / 25卷 / 12期

关键词：

D O I：

10.1038/sj.jp.7211380

中图分类号：

学科分类号：

摘要：

Objective: To review our experience of caspofungin in the treatment of persistent candidemia in the neonatal intensive care unit. Study design: This was a retrospective chart review on 13 infants in whom caspofungin was added to conventional antifungals (amphotericin B and/or fluconazole or flucytosine) for the treatment of refractory candidemia. Results: A total of 12 infants were preterm (gestational age, 24 to 28 weeks) and one was term; the median birth weight was 800g (range, 530 to 5600g). Candidemia (Candida albicans in five, C. parapsilosis in six, C. albicans and C. parapsilosis in one and C. tropicalis in one) persisted despite 6 to 30 days of conventional antifungal therapy. After the addition of caspofungin, sterilization of blood cultures was achieved in 11 infants at the median time of 3 days (range, 1 to 21 days). Adverse events included thrombophlebitis (one patient), hypokalemia (two patients) and elevation of liver enzymes (four patients). Three infants had a second episode of candidemia and seven patients died. Conclusion: Caspofungin may be an efficacious addition for treatment of candidemia refractory to conventional antifungal therapy. This drug should be further investigated in neonates. © 2005 Nature Publishing Group All rights reserved.

引用

页码：770 / 777

页数：7

共 34 条

[1]

Kaufman D., Fungal infection in the very low birth weight infant, Curr. Opin. Infect. Dis., 7, pp. 253-259, (2004)

[2]

Leibovitz E., Neonatal candidosis: Clinical picture, management controversies and consensus and new therapeutic options, J. Antimicrob. Chemother., 49, SUPPL. 1, pp. 69-73, (2002)

[3]

Benjamin Jr D.K., De Long E.R., Steinbach W.J., Et al., Empirical therapy for neonatal candidemia in very low birth weight infants, Pediatrics, 112, pp. 543-547, (2003)

[4]

Chapman R.L., Candida infections in the neonate, Curr. Opin. Pediatr., 15, pp. 97-102, (2003)

[5]

Chapman R.L., Faix R.G., Persistently positive cultures and outcome in invasive neonatal candidiasis, Pediatr. Infect. Dis. J., 19, pp. 822-827, (2000)

[6]

Pappas P.G., Rex J.H., Lee J., Et al., A prospective observational study of candidemia: Epidemiology, therapy and influences on mortality in hospitalized adult and pediatric patients, Clin. Infect. Dis., 37, pp. 634-643, (2003)

[7]

Saiman L., Ludington E., Dawson J.D., Et al., Risk factors for Candida species colonization of neonatal intensive care unit patients, Pediatr. Infect. Dis. J., 20, pp. 1119-1124, (2001)

[8]

Denning D.W., Echinocandin: Antifungal drugs, Lancet, 362, pp. 1142-1151, (2003)

[9]

Ostrosky-Zeichner L., Rex J.H., Pappas P.G., Et al., Antifungal susceptibility survey of 2000 blood stream Candida isolates in the United States, Antimicrob. Agents Chemother., 47, pp. 3149-3154, (2003)

[10]

Pappas P.G., Rex J.H., Sobel J.D., Et al., Guidelines for treatment of candidiasis, Clin. Infect. Dis., 38, pp. 161-189, (2004)

← 1 2 3 4 →